Opicapone (Ongentys)

Opicapone (Ongentys)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Opicapone (Ongentys)</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Current Position</td>
</tr>
<tr>
<td class="label">Regulatory status</td>
<td>Approved in EU (2016), US FDA (2017), and multiple other regions</td>
</tr>
<tr>
<td class="label">Typical dose</td>
<td>50 mg once daily at bedtime</td>
</tr>
<tr>
<td class="label">Main evidence strength</td>
<td>Reduction in OFF time and increase in ON time in patients with motor fluctuations</td>
</tr>
<tr>
<td class="label">Disease-modification signal</td>
<td>None — symptomatic adjunct therapy only</td>
</tr>
<tr>
<td class="label">Key advantage over entacapone</td>
<td>Once-daily dosing vs.

Opicapone (Ongentys)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Opicapone (Ongentys)</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Current Position</td>
</tr>
<tr>
<td class="label">Regulatory status</td>
<td>Approved in EU (2016), US FDA (2017), and multiple other regions</td>
</tr>
<tr>
<td class="label">Typical dose</td>
<td>50 mg once daily at bedtime</td>
</tr>
<tr>
<td class="label">Main evidence strength</td>
<td>Reduction in OFF time and increase in ON time in patients with motor fluctuations</td>
</tr>
<tr>
<td class="label">Disease-modification signal</td>
<td>None — symptomatic adjunct therapy only</td>
</tr>
<tr>
<td class="label">Key advantage over entacapone</td>
<td>Once-daily dosing vs. every-2-3 hour levodopa dosing; superior COMT inhibition</td>
</tr>
<tr>
<td class="label">Major practical benefit</td>
<td>Simplified treatment regimen, reduced pill burden</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Time to peak plasma</td>
<td>~2-3 hours</td>
</tr>
<tr>
<td class="label">Elimination half-life</td>
<td>~1.5-2 hours (but enzyme inhibition lasts 24+ hours)</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>>90%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Primarily hepatic (CYP2C8, CYP2C9)</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Primarily fecal</td>
</tr>
<tr>
<td class="label">Clinical context</td>
<td>Typical approach</td>
</tr>
<tr>
<td class="label">Adjunct to levodopa/carbidopa with motor fluctuations</td>
<td>50 mg once daily at bedtime</td>
</tr>
<tr>
<td class="label">Dose adjustment</td>
<td>May reduce levodopa dose by 10-30% based on response</td>
</tr>
<tr>
<td class="label">Administration</td>
<td>Can be taken with or without food; must be at least 1 hour before or after levodopa</td>
</tr>
<tr>
<td class="label">Co-medication</td>
<td>Interaction mechanism</td>
</tr>
<tr>
<td class="label">Non-selective MAO inhibitors</td>
<td>Potential hypertensive crisis</td>
</tr>
<tr>
<td class="label">Iron supplements</td>
<td>Reduced opicapone absorption</td>
</tr>
<tr>
<td class="label">Cholestyramine</td>
<td>Reduced opicapone absorption</td>
</tr>
<tr>
<td class="label">Strong CYP2C8/2C9 inhibitors</td>
<td>May increase opicapone exposure</td>
</tr>
<tr>
<td class="label">Dopamine antagonists (antipsychotics)</td>
<td>May reduce levodopa efficacy</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Entacapone</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Every levodopa dose</td>
</tr>
<tr>
<td class="label">COMT inhibition</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver monitoring</td>
<td>Not required</td>
</tr>
<tr>
<td class="label">Efficacy (OFF time reduction)</td>
<td>~30 min</td>
</tr>
<tr>
<td class="label">Tolerability</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Pill burden</td>
<td>High</td>
</tr>
</table>

Opicapone is a third-generation, once-daily catechol-O-methyltransferase (COMT) inhibitor approved as an adjunct therapy to levodopa/carbidopa or levodopa/benserazide in adult patients with Parkinson's disease (PD) and end-of-dose motor fluctuations.[@european][@ferreira2016][@lees2017] Developed by BIAL Pharmaceuticals, opicapone represents a significant advancement in COMT inhibition due to its prolonged duration of enzyme inhibition, simple once-daily dosing, and strong clinical efficacy data from the BIPARK-1 and BIPARK-2 pivotal trials.[@ferreira2016][@lees2017][@odin2015]

For Parkinson's disease management, opicapone addresses a fundamental pharmacologic limitation: levodopa's short plasma half-life (~1-2 hours) leads to fluctuating dopamine levels and motor fluctuations (wearning-off phenomenon). By blocking COMT-mediated levodopa metabolism in the periphery, opicapone extends levodopa's therapeutic window and provides more stable dopaminergic stimulation.[@mann1995][@contin2010]

Quick Clinical Snapshot

Mechanistic Rationale

COMT Inhibition and Levodopa Pharmacokinetics

COMT is the primary enzyme responsible for peripheral levodopa metabolism, converting levodopa to 3-O-methyldopa (3-OMD) in the bloodstream. This peripheral metabolism limits levodopa's availability to cross the [blood-brain barrier](/entities/blood-brain-barrier), requiring high doses and frequent administration.[@mann1995][@nutt1984]

First-generation COMT inhibitors like entacapone provided modest benefit but required co-administration with every levodopa dose (typically 4-5 times daily), creating pill burden and adherence challenges.[@parkinson1997] Tolcapone, a second-generation agent, offered more potent COMT inhibition but required liver function monitoring due to hepatotoxicity concerns.[@waters2007]

Opicapone is a third-generation COMT inhibitor with several key advantages:

Impact on Dopaminergic Tone

By reducing peripheral levodopa metabolism, opicapone increases levodopa's bioavailability, extends its plasma half-life, and produces more sustained dopamine receptor stimulation in the striatum.[@mann1995][@contin2010] This translates clinically to:

• Reduced OFF time (periods when Parkinson's symptoms return)
• Increased ON time (periods of good motor function)
• Reduced levodopa dose requirements in some patients
• Improved quality of life measures[@ferreira2016][@lees2017][@odin2015]

Pathway Diagram

Pathway Diagram

Clinical Evidence in Parkinson's Disease

BIPARK-1: Efficacy and Dose-Finding

BIPARK-1 was a randomized, double-blind, placebo-controlled Phase 3 trial evaluating opicapone in patients with Parkinson's disease and motor fluctuations.[@ferreira2016] The study enrolled 600 patients across Europe and compared three doses of opicapone (5 mg, 25 mg, 50 mg) versus placebo as adjunct to levodopa/carbidopa.

Key Results:

• 50 mg opicapone significantly reduced daily OFF time by approximately 1 hour versus placebo (p<0.001)[@ferreira2016]
• Corresponding increase in ON time without troublesome dyskinesia[@ferreira2016]
• Dose-dependent efficacy observed, with 50 mg showing the strongest effect[@ferreira2016]
• Common adverse events included dyskinesia, constipation, and hallucinations — mostly mild to moderate[@ferreira2016]

BIPARK-2: Confirmatory Trial

BIPARK-2 served as the confirmatory Phase 3 trial, further establishing opicapone's efficacy and safety profile in a slightly different patient population.[@lees2017] The trial design was similar to BIPARK-1 and confirmed:

• Significant reduction in OFF time with 50 mg opicapone[@lees2017]
• Improved patient-reported outcomes and quality of life measures[@lees2017]
• Consistent safety profile across populations[@lees2017]

Open-Label Extension Studies

Long-term open-label extensions of BIPARK-1 and BIPARK-2 demonstrated sustained efficacy over 2+ years of treatment, with no new safety signals emerging.[@fasano2018][@costa2020] These data support the long-term durability of opicapone's benefit in clinical practice.

Comparative Data: Opicapone vs. Entacapone

Head-to-head comparisons and meta-analyses have established opicapone's superiority over entacapone:

• Greater reduction in OFF time with opicapone (approximately 30-60 minutes more)[@tropsha2019]
• Once-daily versus multiple daily dosing[@tropsha2019]
• Lower pill burden improves adherence[@tropsha2019]
• Opicapone provides more complete COMT inhibition due to its sustained action[@kiss2010]

Real-World Evidence

Post-marketing studies and real-world data have confirmed the clinical trial findings:

• Significant reduction in levodopa daily doses in approximately 40% of patients[@eggert2020]
• Improved adherence compared to entacapone-based regimens[@eggert2020]
• Effective in both early motor fluctuations and advanced disease[@eggert2020]

Pharmacokinetics, Dosing, and Administration

Pharmacokinetic Profile

The key pharmacologic distinction is that while plasma elimination is relatively rapid, the COMT enzyme inhibition is slowly reversible and persists for approximately 24 hours, supporting once-daily dosing.[@european][@kiss2010]

Dosing Framework

Important timing: Opicapone should be taken at least one hour before or after levodopa/carbidopa to avoid competitive absorption issues.[@european]

Special Populations

• Renal impairment: No dose adjustment needed for mild-moderate renal impairment; limited data for severe impairment[@european]
• Hepatic impairment: Use with caution in moderate impairment; not recommended for severe hepatic impairment[@european]
• Elderly: No specific dose adjustment required; monitor for dyskinesia and hallucinations[@european]

Drug Interactions and Contraindications

Key Drug Interactions

Contraindications

• Pheochromocytoma
• Concurrent use with non-selective MAO inhibitors
• History of neuroleptic malignant syndrome and/or rhabdomyolysis[@european]

Safety and Tolerability

Common Adverse Events

In clinical trials, the most frequently reported adverse events were:

Safety Advantages Over Earlier COMT Inhibitors

Compared to tolcapone, opicapone offers a significantly improved safety profile:

• No liver toxicity: No hepatic transaminase elevation requiring monitoring[@european][@waters2007]
• Peripheral-only action: No central COMT inhibition reduces risk of certain CNS effects[@european]
• Better tolerability: Lower rates of diarrhea and nausea compared to entacapone[@tropsha2019]

Long-Term Safety

Open-label extension studies up to 5 years show maintained safety profile with no new adverse event patterns emerging.[@fasano2018][@costa2020]

Clinical Positioning and Practical Use

Where Opicapone Fits in PD Treatment

Opicapone is positioned as a second-line adjunct therapy for patients experiencing motor fluctuations despite optimized levodopa therapy. Typical placement in treatment algorithms:

• Patients struggling with multiple daily doses
• Patients with inadequate response to entacapone
• Patients prioritizing simplified regimens

Patient Selection Considerations

Good candidates for opicapone:

• Patients with confirmed motor fluctuations (OFF time ≥2 hours daily)
• Patients already on optimized levodopa regimens
• Patients seeking simplified dosing schedules
• Patients who failed or inadequately responded to entacapone

• Patients without motor fluctuations
• Patients with severe hallucinations or psychosis
• Patients on medications with significant interactions

Switching from Entacapone to Opicapone

When switching from entacapone to opicapone:

Comparative Positioning Against Other COMT Inhibitors

Opicapone combines the efficacy advantage of tolcapone with the safety and simplicity profile favorable to entacapone.[@waters2007][@tropsha2019]

Research Priorities and Future Directions

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Opicapone (Ongentys) discovered through SciDEX knowledge graph analysis: